Neuren Pharmaceuticals Ltd has released a press release.
Q1 2024 quarterly activity and cash flow report
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Trofinetide accepted for Priority Review by Health Canada
- Neuren reports profit of $157 million for 2023
- Appendix 4E and 2023 full year accounts
- DAYBUE net sales US$87.1 million in Q4 2023
- Comment on research report
Later from Neuren Pharmaceuticals
- DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m
- Phase 2 trial shows significant improvements in Pitt Hopkins
- Q2 2024 update
- Phase 2 trial shows significant improvements in Angelman
- NEU continues PMS P3 preparations after positive FDA meeting
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals